GlycoNex (4168) - Total Assets
Based on the latest financial reports, GlycoNex (4168) holds total assets worth NT$1.55 Billion TWD (≈ $48.92 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 4168 net assets for net asset value and shareholders' equity analysis.
GlycoNex - Total Assets Trend (2017–2024)
This chart illustrates how GlycoNex's total assets have evolved over time, based on quarterly financial data.
GlycoNex - Asset Composition Analysis
Current Asset Composition (December 2024)
GlycoNex's total assets of NT$1.55 Billion consist of 36.6% current assets and 63.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.3% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how GlycoNex's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of GlycoNex.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GlycoNex's current assets represent 36.6% of total assets in 2024, an increase from 31.9% in 2017.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 23.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GlycoNex Competitors by Total Assets
Key competitors of GlycoNex based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
GlycoNex - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.24 | 2.03 | 19.52 |
| Quick Ratio | 11.24 | 2.03 | 19.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$673.08 Million | NT$271.78 Million | NT$473.59 Million |
GlycoNex - Advanced Valuation Insights
This section examines the relationship between GlycoNex's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.85 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -15.2% |
| Total Assets | NT$1.32 Billion |
| Market Capitalization | $83.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values GlycoNex's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GlycoNex's assets decreased by 15.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GlycoNex (2017–2024)
The table below shows the annual total assets of GlycoNex from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.32 Billion ≈ $41.48 Million |
-15.22% |
| 2023-12-31 | NT$1.55 Billion ≈ $48.92 Million |
-9.56% |
| 2022-12-31 | NT$1.72 Billion ≈ $54.09 Million |
+23.08% |
| 2021-12-31 | NT$1.40 Billion ≈ $43.95 Million |
-11.37% |
| 2020-12-31 | NT$1.57 Billion ≈ $49.59 Million |
+18.15% |
| 2019-12-31 | NT$1.33 Billion ≈ $41.97 Million |
-14.70% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.21 Million |
-16.32% |
| 2017-12-31 | NT$1.87 Billion ≈ $58.80 Million |
-- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more